NeuroPace, Inc. (NASDAQ:NPCE) Insider Martha Morrell Sells 3,200 Shares

NeuroPace, Inc. (NASDAQ:NPCE) insider Martha Morrell sold 3,200 shares of the firm’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $15.01, for a total transaction of $48,032.00. Following the transaction, the insider now directly owns 87,062 shares of the company’s stock, valued at $1,306,800.62. This represents a 3.55 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

NeuroPace Stock Performance

NPCE traded down $0.11 during trading hours on Tuesday, reaching $14.13. The company’s stock had a trading volume of 99,653 shares, compared to its average volume of 141,674. The company’s 50-day moving average is $11.44 and its 200-day moving average is $8.69. NeuroPace, Inc. has a 52 week low of $5.45 and a 52 week high of $18.15. The firm has a market cap of $421.78 million, a PE ratio of -14.13 and a beta of 2.02. The company has a debt-to-equity ratio of 6.03, a quick ratio of 4.77 and a current ratio of 5.59.

NeuroPace (NASDAQ:NPCE) last posted its earnings results on Tuesday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.07. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The company had revenue of $21.06 million during the quarter, compared to analysts’ expectations of $19.33 million. During the same quarter last year, the company posted ($0.28) EPS. On average, equities analysts forecast that NeuroPace, Inc. will post -1 EPS for the current year.

Institutional Investors Weigh In On NeuroPace

A number of institutional investors have recently made changes to their positions in NPCE. KCK LTD. acquired a new stake in NeuroPace during the 4th quarter worth approximately $58,981,000. Millennium Management LLC increased its position in NeuroPace by 13.3% during the 2nd quarter. Millennium Management LLC now owns 686,037 shares of the company’s stock worth $5,186,000 after buying an additional 80,324 shares during the period. Geode Capital Management LLC lifted its holdings in shares of NeuroPace by 8.7% during the third quarter. Geode Capital Management LLC now owns 317,192 shares of the company’s stock worth $2,211,000 after buying an additional 25,330 shares in the last quarter. State Street Corp boosted its position in shares of NeuroPace by 9.1% in the third quarter. State Street Corp now owns 155,490 shares of the company’s stock valued at $1,084,000 after acquiring an additional 12,912 shares during the period. Finally, XTX Topco Ltd grew its stake in shares of NeuroPace by 56.1% in the second quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock valued at $182,000 after acquiring an additional 8,643 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on NPCE shares. JPMorgan Chase & Co. increased their target price on shares of NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th. UBS Group initiated coverage on NeuroPace in a report on Tuesday, January 21st. They issued a “buy” rating and a $17.00 price objective for the company. Finally, Wells Fargo & Company lowered their target price on shares of NeuroPace from $15.00 to $13.00 and set an “overweight” rating on the stock in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, NeuroPace has a consensus rating of “Moderate Buy” and a consensus target price of $15.33.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.